

Vincent Idemyor, PharmD, is a pharmacist, clinical pharmacologist, healthcare executive, and academic leader with more than thirty-five years of experience in pharmaceutical sciences, hospital administration, global health, and precision medicine. He received his Doctor of Pharmacy from the University of Minnesota College of Pharmacy in 1986 and from 1987 to 1990 held clinical pharmacy and pharmacology appointments at United Samaritans Medical Center in Danville, Illinois, before training in clinical pharmacology at the University of Illinois College of Medicine in Chicago.

From 1991 to 1999, Dr. Idemyor served as Head of Clinical Pharmacology at Mercy Hospital and Medical Center, where his team was among the first to characterize extended-spectrum beta-lactamase activity responsible for antibiotic resistance in intensive care units in the Chicago region. He subsequently directed pharmacy services at Advocate Health Care (2000 to 2006) and Saint Margaret Mercy Healthcare Centers (2007 to 2008), managing multi-million-dollar budgets and leading large multidisciplinary teams. Across his career he has exercised fiscal responsibility for cumulative budgets exceeding \$150 million and has secured and administered more than \$160 million in competitive grants and institutional funding.

In 2006 and 2007, Dr. Idemyor served as a consultant to the United Nations and lead investigator for a nationwide evaluation of Global Fund-supported HIV, tuberculosis, and malaria programs throughout Nigeria. Since 2011 he has held a Distinguished Visiting Scholar and Professor appointment at the University of Port Harcourt, where he was a founding contributor to the Faculty of Pharmaceutical Sciences. He chairs the International Scientific Advisory Board of the Africa Centre of Excellence for Public Health and Toxicological Research (ACE-PUTOR) and advises the University's proposed Graduate Institute of Climate Change Studies, a World Bank-supported initiative.

Dr. Idemyor is the author of 45 peer-reviewed publications and book chapters spanning HIV therapeutics, antimicrobial resistance, pharmacogenomics, global health, and precision medicine. He was selected as a LEADS Scholar by Nigeria's National Universities Commission in 2011 and, in 2023, received the Donald E. Francke Medal from the American Society of Health-System Pharmacists, the Society's highest honor.

Since 2017, Dr. Idemyor has collaborated with Joseph Grossman, MD, LCSW, in the development of precision opioid tapering technologies and pharmaceutical manufacturing strategies. Their professional relationship spans nearly three decades and encompasses research and development across multiple areas of pharmaceutical medicine and therapeutics.

PROFESSIONAL AWARDS AND PRIZES

- 2023 American Society of Health-System Pharmacists (ASHP) Donald E. Francke Medal
- 2007 Medical Award of the Year — National Technical Association, Inc.
- 2004 Outstanding Achievement Award — Chicago Commission on Human Relations
- 2003 Red Ribbon Award — Illinois Department of Public Health
- 2002 Benjamin Banneker Award for Science and Technology
- 2001 Research and Publications Achievement Award — ABHP
- 2002–2004 Multiple MVP (Mission, Values, and Philosophy) Awards — Advocate Health Care (service delivery, education, and excellence)

PEER-REVIEWED PUBLICATIONS AND BOOK CHAPTERS (45 TOTAL)

1. Muoghalu BU, Udeani GO, Idemyor VT. Naloxone therapy in stroke. *Clinical Pharmacy* 1989; Vol. 8. [Letter to the Editor]
2. Idemyor V, Cherubin CE. Pleurocerebral nocardia in a patient with human immunodeficiency virus. *The Annals of Pharmacotherapy* 1992; 26:188–189.
3. Idemyor V, Cherubin CE. Rapidly progressing mesothelioma in an HIV-positive patient. *The Annals of Pharmacotherapy* 1992; 26:429.
4. Idemyor V, Cherubin CE, Kuritza A. Multiresistant *Klebsiella pneumoniae* in two Chicago hospitals. *Infectious Disease Newsletter*, September 1992.
5. Idemyor V, Cherubin CE. Retroperitoneal abscess caused by *Mycobacterium chelonae* and treatment. *The Annals of Pharmacotherapy* 1993; 27:178–179.
6. Idemyor V. *Mycobacterium tuberculosis*: resurgence of an old disease — current problems. *Journal of the National Medical Association* 1993; 85(2):95–96.
7. Idemyor V. Human immunodeficiency virus (HIV) infection epidemic: medical and social issues and the unresolved dilemmas. *Journal of the National Medical Association* 1993; 85(10):741–743.
8. Idemyor V. Bacterial resistance to antimicrobial agents — the time for concern. *The Annals of Pharmacotherapy* 1993; 27:1285. [Letter to the Editor]
9. Cherubin CE, Idemyor V, Kuritza A, Oelher M, Rasmussen BA, Bradford PA, Bush K. Ceftazidime hydrolyzing β -lactamase from *Klebsiella pneumoniae* from two Chicago hospitals. 93rd Annual Meeting of American Society for Microbiology, Atlanta, Georgia, 1993.
10. Bradford PA, Cherubin CE, Idemyor V, Kuritza A, Rasmussen BA, Bush K. TEM-10 and TEM-12 ceftazidime hydrolyzing β -lactamases from a single isolate of *Klebsiella pneumoniae*. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993.
11. Idemyor V. The acquired immunodeficiency syndrome (AIDS) epidemic: can the African countries be optimistic? *The Annals of Pharmacotherapy* 1994; 28:286.
12. Bradford PA, Cherubin CE, Idemyor V, Rasmussen BA, Bush K. Multiply resistant *Klebsiella pneumoniae* from two Chicago hospitals: identification of the extended spectrum TEM-12 and TEM-10 ceftazidime hydrolyzing β -lactamases in a single isolate. *Antimicrobial Agents and Chemotherapy* 1994; 38:761–766.

13. Idemyor V. Selective decontamination of the digestive tract in the intensive care unit. *Journal of the National Medical Association* 1994; 86(6). [Letter to the Editor]
14. Idemyor V. Resistencia bacteriana a los agentes antimicrobianos: ya es hora de tenerlo en cuenta. *The Annals of Pharmacotherapy* (Ed. Esp.) 1994; 2(2):125–126.
15. Terzian CG, Idemyor V, Jarrel R. Penicillinase producing gonococcal arthritis in a community hospital. *Journal of the National Medical Association* 1994; 86(8):624–626.
16. Idemyor V. HIV infection: what difference have we made on the course of disease and where do we go from here. *Journal of the National Medical Association* 1994; 86(10):737–739.
17. Idemyor V. Antimicrobial drug resistance among common pathogens in American hospitals: when will the microbe stop winning? *Journal of the National Medical Association* 1998; 90(1):10–12.
18. Idemyor V. Using non-nucleoside reverse transcriptase inhibitors in treating HIV disease: where are the therapeutic niches? *Journal of the National Medical Association* 2000; 92(2):99–101.
19. Idemyor V. HIV resistance and tolerability issues in antiretroviral therapy. *Journal of the National Medical Association* 2001; 93(4):151–153.
20. Idemyor V. Continuing debate over HIV therapy initiation. *HIV Clinical Trials* 2002; 3(2):173–176.
21. Idemyor V. It's time to step up the management of community acquired pneumonia. *Journal of the National Medical Association* 2002; 94(3):178–181.
22. Idemyor V. Human immunodeficiency viruses and drug therapy: resistance and implications for antiretroviral therapy. *Pharmacotherapy* 2002; 22(5):659–662.
23. Idemyor V, Smith SW. Biological warfare — a growing healthcare concern. *The Annals of Pharmacotherapy* 2002; 36:1282–1286.
24. Idemyor V. Promising HIV/AIDS microbicide approach for prevention of human immunodeficiency virus needs more support. *Pharmacotherapy* 2002; 22(8):1074–1076.
25. Idemyor V. The evolving role of antiretroviral drug resistant testing in HIV-infected individuals. *HIV Clinical Trials* 2002; 3(5):413–417.
26. Idemyor V. 20 years since human immunodeficiency virus (HIV) discovery: considerations for the next decade. *Pharmacotherapy* 2003; 23(3):384–387.
27. Idemyor V. The concept of structured treatment interruptions in the management of patients with human immunodeficiency virus (HIV) disease: where are we currently? *HIV Clinical Trials* 2003; 4(2):79–83.
28. Idemyor V. Emerging opportunistic fungal infections: where are we heading? *Journal of the National Medical Association* 2003; 95(12):1211–1215.
29. Idemyor V. Human immunodeficiency virus: scientific challenges impeding candidate vaccines. *HIV Clinical Trials* 2003; 4(6):421–424.
30. Idemyor V. The International AIDS Conference 2004 and how to globally counter HIV/AIDS. *HIV Clinical Trials* 2005; 6(1):43–49.
31. Idemyor V. Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies? *HIV Clinical Trials* 2005; 6(5):272–277.
32. Idemyor V. Human immunodeficiency virus/acquired immune deficiency syndrome: clinical testing challenges. In: Smith CG, O'Donnell JT (eds). *The Process of New Drug Discovery and Development*. 2nd ed. New York: Informa Healthcare USA, Inc; 2006:459–470.
33. Idemyor V. Human immunodeficiency virus (HIV) and malaria interaction in sub-Saharan Africa: the collision of two titans. *HIV Clinical Trials* 2007; 8(5):246–253.
34. Idemyor V. HIV and tuberculosis co-infection: inextricably linked liaison. *Journal of the National Medical Association* 2007; 99(12):1414–1419.
35. Idemyor V. Book review: *Scientific Errors and Controversies in the U.S. HIV/AIDS Epidemic: How They Slowed Advances and Were Resolved* (Holmberg SD). *HIV Clinical Trials* 2008; 9(6):450–452.

36. Idemyor V. Diabetes in sub-Saharan Africa: health care perspectives, challenges, and the economic burden of disease. *Journal of the National Medical Association* 2010; 102(7):650–653.
37. Idemyor V. Lassa virus infection in Nigeria: clinical perspective overview. *Journal of the National Medical Association* 2010; 102(12):1243–1246.
38. Idemyor V. Contributing Author: *Nigeria Health Review 2010 — Non-Communicable Diseases in Nigeria: The Emerging Epidemic*. ISBN: 978-928-917-524-6.
39. Idemyor V. HIV pharmacotherapy and its complications. In: O'Donnell JT (ed). *Drug Injury: Liability, Analysis and Prevention*. 3rd ed. Tucson: Lawyers & Judges Publishing Company, Inc; 2012:507–514.
40. Idemyor V. Genomic medicine: health care issues and the unresolved ethical and social dilemmas. *American Journal of Therapeutics* 2014; 21:548–553.
41. Idemyor V. HIV pharmacotherapy and its complications. In: O'Donnell JT, O'Donnell JJ (eds). *O'Donnell's Drug Injury*. 4th ed. Tucson: Lawyers & Judges Publishing Company, Inc; 2016:375–382.
42. Idemyor V. Pharmacogenomics: using precision medicine to decrease adverse drug reactions. In: O'Donnell JT, O'Donnell JJ (eds). *O'Donnell's Drug Injury*. 4th ed. Tucson: Lawyers & Judges Publishing Company, Inc; 2016:639–644.
43. Idemyor V. Clinical testing challenges in HIV/AIDS research. In: O'Donnell JJ III, Somberg J, Idemyor V, O'Donnell JT (eds). *Drug Discovery and Development*. 3rd ed. Boca Raton: CRC Press; 2019:509–520.
44. Erhabor G, Akanmu AS, Egbagbe E, Ejim E, Feldman C, Habib A, Idemyor V, et al. The need for adult pneumococcal vaccination in Nigeria. *West African Journal of Medicine* 2021; 38(s10):S1–S13.
45. Idemyor V. Translational research and implementation science: accelerating the imperative. *American Journal of Health-System Pharmacy* 2024; 81(6):190–198. doi: 10.1093/ajhp/zxad294.